The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies

ConclusionsMany of the current treatment regimens for RRMM have demonstrated clinical effectiveness in trials. Unlike newly diagnosed MM, these regimens are less likely to result in significant improvement in HRQoL in RRMM. This should be communicated to patients before initiating therapies.Implications for Cancer SurvivorsIndividualized therapeutic approach for RRMM should be chosen based on a shared decision-making process that aligns clinical efficacy with patients ’ treatment priorities and HRQoL.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research